Dengue and other flavivirus infections;La dengue et autres infections à flavivirus

OIE Revue Scientifique et Technique

Volumn 34, Issue 2, 2015, Pages 467-472

  Choumet, V ^a   Desprès, Ph ^b  

^a Centre collaborateur de l'Organisation mondiale de la santé animale   (France)

^b UNIVERSITÉ DE LA RÉUNION   (France)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS VACCINE;

AEDES; ANIMAL; DENGUE; DISEASE CARRIER; FLAVIVIRUS INFECTIONS; HEALTH; HUMAN; PHYSIOLOGY; VIROLOGY;

AEDES; ANIMALS; DENGUE; FLAVIVIRUS INFECTIONS; GLOBAL HEALTH; HUMANS; INSECT VECTORS; VIRAL VACCINES;

EID: 84945279017     PISSN: 02531933     EISSN: 16080645     Source Type: Journal    
DOI: 10.20506/rst.34.2.2372     Document Type: Article

References (25)

1. Weaver S.C. & Reisen WK. (2010).-Present and future arboviral threats. Antiviral Res, 85 (2), 328-345. doi: 10.1016/j.antiviral.2009.10.008.
2. Quaresma J.A, Pagliari C, Medeiros D.B, Duarte M.I. & Vasconcelos RE (2013).-Immunity and immune response, pathology and pathologic changes: progress and challenges in the immunopathology of yellow fever. Rev. Med. Virol., 23 (5), 305-318. doi: 10.1002/rmv.l752.
3. Cottin P, Niedrig M. & Domingo C. (2013).-Safety profile of the yellow fever vaccine Stamaril11: a 17-year review. Expert Rev. Vaccines, 12 (11), 1351-1368.
4. Tangy E & Desprès P. (2014).-Yellow fever vaccine attenuation revealed: loss of diversity. J. Infect. Dis, 209 (3), 318-320. doi: 10.1093/infdis/jit551.
5. Hayes E.B. (2009).-Zika virus outside Africa. Emerg. Infect. Dis, 15 (9), 1347-1350.
6. Musso D, Nilles EJ. & Cao-Lormeau VM. (2014).-Rapid spread of emerging Zika virus in the Pacific area. Clin. Microbiol. Infect., 20 (10), 0595-0596. doi: 10.1111/1469-0691.12707.
7. Kyle J.L. & Harris E. (2008).-Global spread and persistence of dengue. Annu. Rev. Microbiol, 62, 71-92. doi: 10.1146/annurev.micro.62.081307.163005.
8. Thomas S.J, Strickman D. & Vaughn D.W (2003).-Dengue epidemiology: virus, epidemiology, ecology, and emergence. Adv. Virus Res, 61, 235-289.
9. Weaver S.C. & Vasilakis N. (2009).-Molecular evolution of dengue viruses: contributions of phylogenetics to understanding the history and epidemiology of the preeminent arboviral disease. Infect. Genet. Evol., 9 (4), 523-540. doi: 10.1016/j.meegid.2009.02.003.
10. Green S. & Rothman A. (2006).-Immunopathological mechanisms in dengue and dengue hemorrhagic fever. Curr. Opin. Infect. Dis, 19 (5), 429-436.
11. Gubler D.J. (1998).-Dengue and dengue hemorrhagic fever. Clin. Microbiol. Rev, 11 (3), 480-496.
12. Whitehorn J. & Simmons CE (2011).-The pathogenesis of dengue. Vaccine, 29 (42), 7221-7228. doi: 10.1016/j.vaccine.2011.07.022.
13. Carrington L.B. & Simmons CE (2014).-Human to mosquito transmission of dengue viruses. Front. Immunol, 5, 290. doi: 10.3389/fimmu.2014.00290.
14. Briant L, Desprès P, Choumet V & Misse D. (2014).-Role of skin immune cells on the host susceptibility to mosquito-borne viruses. Virology, 464-465, 26-32. doi: 10.1016/j.virol.2014.06.023.
15. Slatko B, Luck A.N, Dobson S.L. & Foster J.M. (2014).-Wolbachia endosymbionts and human disease control. Molec. Biochem. Parasitol, 195 (2), 88-95.
16. Grange L, Simon-Loriere E, Sakuntabhai A, Gresh L, Paul R. & Harris E. (2014).-Epidemiological risk factors associated with high global frequency for inapparent dengue virus infections. Front. Immunol, 5, 280. doi: 10.3389/fimmu.2014.00280.
17. Potts J.A. & Rothman A.L. (2008).-Clinical and laboratory features that distinguish dengue from other febrile illnesses in endemic populations. Trop. Med. Int. Hlth, 13 (11), 1328-1340. doi: 10.1111/j.l365-3156.2008.02151.x.
18. Horstick O, Jaenisch T, Martinez E, Kroeger A, See L.L.C, Farrar J. & Ranzinger S.R. (2014).-Comparing the usefulness of the 1997 and 2009 WHO dengue case classification: a systematic literature review. Am. J. Trop. Med. Hyg., 91 (3), 621-634. doi: 10.4269/ajtmh.l3-0676.
19. Programme spécial de recherche et de formation sur les maladies tropicales (TDR) /Organisation mondiale de la santé (OMS) (2009).-Dengue: Guidelines for diagnosis, treatment, prevention and control. TRD/OMS, Genève.
20. Herrero L.J, Zakhary A, Gahan M.E, Nelson M.A, Herring B.L, Hapel AJ, Keller RA, Obeysekera M, Chen W, Sheng K.C, Taylor A, Wolf S, Bettadpura J, Broor S, Dar L. & Mahalingam S. (2013).-Dengue virus therapeutic interventions strategies based on viral, vector and host factors involved in disease pathogenesis. Pharmacol Therapeut., 137 (2), 266-282. doi: 10.1016/j.pharmthera.2012.10.007.
21. Chanama S, Anantapreecha S, A-nuegoonpipat A, Sa-gnasang A, Kurane I. & Sawanpanyalert E (2004).-Analysis of specific IgM responses in secondary infections: levels and positive rates in comparison with primary infections. J. Clin. Virol, 31 (3), 185-189.
22. Guzman M.G. & Kouri G. (2004).-Dengue diagnosis advances and challenges. Int. J. Infect. Dis, 8 (2), 69-80.
23. Kong Y.Y, Thay CH. & Tin T.C. (2006).-Rapid detection, serotyping and quantification of dengue viruses by Taqman real-time one-step RT-PCR. J. Virol. Meth, 138 (1-2), 123-130.
24. Kuno G, Gómez I. & Gubler D.J. (1991).-An ELISA procedure for the diagnosis of dengue infections. J. Virol. Meth, 33 (1-2), 101-113.
25. Yauch L.E. & Shresta S. (2014).-Dengue virus vaccine development. Adv. Virus Res, 88, 315-372. doi: 10.1016/B978-0-12-800098-4.00007-6.